Orziloben granted Orphan Drug Designation in the U.S. and European UnionCompany expects to report topline results from Phase 2 study in Q3 2026AMSTERDAM--(BUSINESS WIRE)--NorthSea Therapeutics B.V.

Orziloben granted Orphan Drug Designation in the U.S. and European Union Company expects to report topline results from Phase 2 study in Q3 2026 NorthSea Therapeutics B.V. ("NorthSea" or the "Company" ...

New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT ...

Johnson & Johnson today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination ...

New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO beyond lung ...

TD Cowen 46th Annual Health Care Conference March 3, 2026 1:50 PM ESTCompany ParticipantsIan Estepan - President ...

BlueBird 6 is the largest ever commercial communications array deployed in low Earth orbit, designed to support cellular broadband peak data speeds of up to 120 Mbps MIDLAND, Texas, February 11, 2026- ...

Insiders seem to have made the most of their holdings by selling US$9.7m worth of AST SpaceMobile, Inc. (NASDAQ:ASTS) stock at an average sell price of US$36.38 during the past year. The company’s ...

Space stocks are having a rough week, with SpaceX rivals AST SpaceMobile and Rocket Lab taking some of the biggest hits. William Gavin is a tech reporter for MarketWatch. He is based in New York.

In the latest close session, AST SpaceMobile, Inc. (ASTS) was down 5.99% at $104.55. The stock fell short of the S&P 500, which registered a gain of 0.54% for the day. Meanwhile, the Dow gained 1.05%, ...

Autophagy is indispensable for maintaining hepatocyte integrity, metabolic homeostasis, and survival. While several autophagy ...